Literature DB >> 356058

Experimental gram-negative bacterial sepsis: reevaluation of the ability of rough mutant antisera to protect mice.

S E Greisman, J B DuBuy, C L Woodward.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 356058     DOI： 10.3181/00379727-158-40231

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN： 0037-9727


× No keyword cloud information.
  21 in total

Review 1.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

Review 2.  Immunotherapeutic advances in the treatment of gram-negative bacterial sepsis.

Authors:  D L Dunn
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

3.  Monoclonal antibodies: technology and application to gram-negative infections.

Authors:  L S Young
Journal:  Infection       Date:  1985       Impact factor: 3.553

4.  Protection of mice against the lethal toxicity of a lipopolysaccharide (LPS) by immunization with anti-idiotype antibody to a monoclonal antibody to lipid A from Eikenella corrodens LPS.

Authors:  T Kato; I Takazoe; K Okuda
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

5.  Antiserum against Escherichia coli J5: a re-evaluation of its in vitro and in vivo activity against heterologous gram-negative bacteria.

Authors:  M Trautmann; H Hahn
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

Review 6.  Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients.

Authors:  A Cometta; J D Baumgartner; M P Glauser
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

7.  Immunization against bacteria- and endotoxin-induced hypotension.

Authors:  A M Abdelnoor; A G Johnson; A Anderson-Imbert; A Nowotny
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

8.  Antibody specific for Escherichia coli J5 cross-reacts to various degrees with an Escherichia coli clinical isolate grown for different lengths of time.

Authors:  D E McCallus; N L Norcross
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

9.  Isolation and characterization of murine monoclonal antibodies specific for gram-negative bacterial lipopolysaccharide: association of cross-genus reactivity with lipid A specificity.

Authors:  W C Bogard; D L Dunn; K Abernethy; C Kilgarriff; P C Kung
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

10.  Use of mucin and hemoglobin in experimental murine gram-negative bacteremia enhances the immunoprotective action of antibodies reactive with the lipopolysaccharide core region.

Authors:  B J Appelmelk; A M Verwey-van Vught; J J Maaskant; W F Schouten; L G Thijs; D M Maclaren
Journal:  Antonie Van Leeuwenhoek       Date:  1986       Impact factor: 2.271
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.